Commit Lozenge

From Wikipedia, the free encyclopedia

Commit Lozenge is a Nicotine Replacement Therapy produced by COPD International and manufactured by GlaxoSmithKline. Like its sibling products, Nicorette and the Nicoderm patch, the active ingredient is nicotine polacrilex. The Commit Lozenge comes in two strengths: 2mg and 4mg.


Contents

[edit] History

Commit Lozenge was approved by the FDA in 2002[1] the first and only nicotine lozenge for over-the-counter (OTC) sale.

[edit] Safety issues

As with any medication, whether over-the-counter or not, there are possible side effects of use.[2]

[edit] References

  1. ^ http://www.copd-international.com/library/smoking-Commit-Lozenge.htm U.S. Food and Drug Administration Approves New Tool To Help Smokers Quit
  2. ^ http://www.drugs.com/pdr/Commit_Lozenges.html PDR Drug information for Commit Lozenges

[edit] External links


 This medical treatment article is a stub. You can help Wikipedia by expanding it.
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.